1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001C2241, NCT00419159
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001C2454, NCT00510354
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001C2324, NCT00510068
|
|
4.
|
Phase: Phase III
Type: Genetics, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 44, EudraCT No.: 2006-005834-19, NCT00567554
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001M2301, NCT00789828
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001N2301, EUDRACT 2008-000498-40, NCT00790036
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001M2302, NCT00790400
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2007.489/32, NCT00799188
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001Y2301, EUDRACT Number: 2008-008698-69, NCT00863655
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001J2301, EUDRACT Number: 2008-006556-21, NCT00876395
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001R2301, EUDRACT No. - 2008-006544-20, NCT00879333
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2004-0758, NCT00253318
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005-0471, NCT00317720
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and over
Sponsor: Other
Protocol IDs: UCSF06523, NCT00384969
|
|
15.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: CRAD001C2453, NCT00390195
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI GU 44, CRAD001C2480, NCT00392821
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1342-2004, NCT00406276
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001J2101, NCT00426556
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001C2111, NCT00456833
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001C2114, NCT00457119
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CCHMC IRB # 04-07-22, NCT00457964
|
|
22.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-LS0689, LS0689, MAYO-07-000710, NCT00474929
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-352, NCT00516165
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GI05-102, NCT00522665
|
|
25.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N057K, N057K, NCT00553150
|
